Referenced in: none

Automatically associated channels: Nav1.7

Title: Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel.

Authors: J Natkunarajah, D Atherton, F Elmslie, S Mansour, P Mortimer

Journal, date & volume: Clin. Exp. Dermatol., 2009 Dec , 34, e640-2

PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/19549232

Abstract
Primary erythermalgia (erythromelalgia) is a rare autosomal dominant condition characterized by intermittent attacks of erythema, increased skin temperature and severe burning pain in the extremities, in a bilateral symmetrical distribution. Mutations in the SCN9A gene, which encodes a voltage-gated sodium channel have been shown to cause this disease. We report a family identified to have a mutation in the SCN9A gene, in which one severely affected family member has responded to the therapeutic combination of gabapentin and carbamazepine treatment.